Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine

dc.contributor.author	Erguven, M.
dc.contributor.author	Bilir, A.
dc.contributor.author	Yazihan, N.
dc.contributor.author	Korkmaz, S.
dc.contributor.author	Aktas, E.
dc.contributor.author	Ovalioglu, C.
dc.contributor.author	Dundar, T.
dc.contributor.author	Seyithanoglu, H.
dc.date.accessioned	2021-12-21T08:41:57Z
dc.date.available	2021-12-21T08:41:57Z
dc.date.issued	2012
dc.identifier.issn	17921074
dc.identifier.uri	https://doi.org/10.3892/ol.2011.434
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1559
dc.description.abstract	The purpose of the present study was to overcome resistance to imatinib (IM) by combining it with roscovitine (ROSC) and to investigate whether or not midkine (MK) had an effect on this combination in the treatment of glioblastoma (GBL). Human T98 GBL cel
dc.language.iso	English
dc.rights	All Open Access, Bronze, Green
dc.title	Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine
dc.type	Article
dc.relation.journal	Oncology Letters
dc.identifier.issue	1
dc.identifier.startpage	200
dc.identifier.endpage	208
dc.identifier.volume	3
dc.identifier.doi	10.3892/ol.2011.434
dc.relation.issue	1
dc.relation.volume	3